Clinical Trial Update: Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating Erlotinib with concurrent radiotherapy in unresectable non-small cell lung cancer harboring activating EGFR mutations in exon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Jinming Yu | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN